Skip to main content
Shahram  Kordasti

Dr Shahram Kordasti

Reader and Group Leader in Applied Cancer Immunopathology

Research interests

  • Cancer
  • Immunology

Biography

Following his graduation from medical school and clinical training in Internal Medicine/Haematology, Dr Kordasti received his MSc in Medical Immunology and PhD in Cancer Immunology from King's College London. He established the role of regulatory T cells (Tregs) in Myelodysplastic Syndrome (MDS) and their effects on disease progression and response to treatment. In 2018, he was appointed as a senior lecturer at King's College London and continued his work, developing an interest in the immunobiology of aplastic anaemia (AA) during this period. He became a reader (Associate Professor) in Applied Cancer Immunopathology in 2022.

He is also an honorary clinical haematologist at Guy’s Hospital, and he has an interest in MDS, AA, and myeloproliferative neoplasms (MPN). His main research interest lies in the plasticity of CD4+ T cells, their interaction with the inflammatory microenvironment, and their role in the immunobiology of myeloid malignancies. Another focus of his research group is computational biology, multidimensional cytometry, and integrating multiomics data for patient stratification. Additionally, he leads an international consortium, i4MDS, focusing on standardising immune monitoring in patients with MDS.

    Research

    systems cancer immunology-banner
    Systems Cancer Immunology

    The main focus of the Systems Cancer Immunology (SCI) group is the role of immune system in the development of Myeloid Malignancies.

    Immunology and Immunotherapy Programme Header
    Cancer Immunology & Immunotherapy

    Cancer Immunology represents a broad field of research that studies host-tumour interactions as therapeutic targets in the treatment of cancer.

    Project status: Ongoing

    News

    King's leads transatlantic consortium to advance immune-monitoring of blood cancer

    King’s will lead institutions across Europe and the US in a new consortium to standardise and improve how we monitor the blood cancer Myelodysplastic Neoplasms.

    Myelodysplastic Neoplasms consortium

    New open-source easy-to-use resource for the analysis of high-dimensional cytometry data launches

    ImmunoCluster provides a computational framework for the non-specialist to profile complex high-dimensional data such as mass and flow cytometry.

    cell floating

    Trial to repurpose cancer drug for patients with COVID-19 launches

    A new trial repurposing a blood cancer drug for patients with COVID-19 is being launched.

    covid cancer drug

    Features

    5 minutes with Shahram Kordasti

    Shahram Kordasti is a Senior Lecturer and Group Leader in Applied Cancer Immunopathology within the School of Cancer & Pharmaceutical Sciences, and an...

    5 minutes with Shahram Kordasti

      Research

      systems cancer immunology-banner
      Systems Cancer Immunology

      The main focus of the Systems Cancer Immunology (SCI) group is the role of immune system in the development of Myeloid Malignancies.

      Immunology and Immunotherapy Programme Header
      Cancer Immunology & Immunotherapy

      Cancer Immunology represents a broad field of research that studies host-tumour interactions as therapeutic targets in the treatment of cancer.

      Project status: Ongoing

      News

      King's leads transatlantic consortium to advance immune-monitoring of blood cancer

      King’s will lead institutions across Europe and the US in a new consortium to standardise and improve how we monitor the blood cancer Myelodysplastic Neoplasms.

      Myelodysplastic Neoplasms consortium

      New open-source easy-to-use resource for the analysis of high-dimensional cytometry data launches

      ImmunoCluster provides a computational framework for the non-specialist to profile complex high-dimensional data such as mass and flow cytometry.

      cell floating

      Trial to repurpose cancer drug for patients with COVID-19 launches

      A new trial repurposing a blood cancer drug for patients with COVID-19 is being launched.

      covid cancer drug

      Features

      5 minutes with Shahram Kordasti

      Shahram Kordasti is a Senior Lecturer and Group Leader in Applied Cancer Immunopathology within the School of Cancer & Pharmaceutical Sciences, and an...

      5 minutes with Shahram Kordasti